Ndubaku, Chudi O.

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2018) · Cell Reports

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 451

USP7 small-molecule inhibitors interfere with ubiquitin binding.

Kategaya, L., Di Lello, P., Rougé, L., Pastor, R., Clark, K. R., Drummond, J., Kleinheinz, T., Lin, E., Upton, J.-P., Prakash, S., et al. (2017) · Nature

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 333

NK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists

Nicolai, C. J., Wolf, N., Chang, I.-C., Kirn, G., Marcus, A., Ndubaku, C. O., McWhirter, S. M., & Raulet, D. H. (2020) · Science Immunology

Immune Cell Function and Interactioninterferon and immune responses

Cited by 268

Discovery of small-molecule inhibitors of ubiquitin specific protease 7 (USP7) using integrated NMR and in silico techniques

Di Lello, P., Pastor, R., Murray, J. M., Blake, R. A., Cohen, F., Crawford, T. D., Drobnick, J., Drummond, J., Kategaya, L., Kleinheinz, T., et al. (2017) · Journal of Medicinal Chemistry

Ubiquitin and proteasome pathwaysComputational Drug Discovery Methods

Cited by 90

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2019) · Cell Reports

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 53